Skip to content

BEMIPHARMA

Active
Private limited company (pre-2019)founded 200619 yrs activeRue Amion(FAR) 12, 6240 Farciennes, BelgiumKBO/BCE: BE 0885.720.658
Summary

BEMIPHARMA has been active since 2006 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €39,375 and a net result of -€179. Equity is shrinking by ~13.3% per year across the filed fiscal years. The computed 12-month bankruptcy probability is 1.1% (low).

Checked score

Score 2025
Axes · tick = 2024
Profitability36▲+2
Solvency100=
Growth58=
Track record100
Bankruptcy probability, 12 months
1.1% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000 at 30 days acceptable
cash: 9.6% of total assets, and 0% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · No NACE activity registered
No NACE activity is registered in the KBO, which is more common among companies that later fail.
KBO · activities
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 19 years 0 20 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
100%
Return on assets
-0.5%
Age of the figures
12 mo
neutral · Filed after the deadline
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 28-05-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
28 d late
2024
19 d late
2023
29 d late
2022
3 d late
2021
23 d late
2020
140 d early
2019
36 d early
← before the deadline after the deadline →
tick = median of all Belgian filings

This company filed its last 7 accounts on average 11 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
28-09-2026 today30-09-2026 close30-04-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

BEMIPHARMA was incorporated on 18 December 2006.1 Total assets fell from EUR 249,080 in 2018 to EUR 39,375 in 2025 and headcount from 2 full-time equivalents in 2018 to 0.6 in 2021.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2018, 2021 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
€39,375▼ 0.5%
2024 · €39,554
Total assets
€39,375▼ 1.5%
2024 · €39,966
Net result
-€179▲ 68.3%
2024 · -€563
Working capital
€39,554▼ 1.4%
2023 · €40,117
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Operating result-€39,814-€2,307▲ 94.2%-€1,377▲ 40.3%-€412▲ 70.1%
Net result-€34,293-€2,575▲ 92.5%-€1,543▲ 40.1%-€563▲ 63.5%-€179▲ 68.3%
Equity€44,236▼ 43.7%€41,661▼ 5.8%€40,117▼ 3.7%€39,554▼ 1.4%€39,375▼ 0.5%
Total assets€48,432▼ 72.5%€42,861▼ 11.5%€40,717▼ 5.0%€39,966▼ 1.8%€39,375▼ 1.5%
Debt€4,196▼ 95.7%€1,200▼ 71.4%€600▼ 50.0%€412▼ 31.4%
Working capital€43,585▼ 35.1%€41,661▼ 4.4%€40,117▼ 3.7%€39,554▼ 1.4%
Staff (FTE)0.6
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
-€40,000-€30,000-€20,000-€10,000€0Operating result 2021: -€39,814-€39,814Net result 2021: -€34,293-€34,293Operating result 2022: -€2,307-€2,307Net result 2022: -€2,575-€2,575Operating result 2023: -€1,377-€1,377Net result 2023: -€1,543-€1,543Operating result 2024: -€412-€412Net result 2024: -€563-€563Net result 2025: -€179-€17920212022202320242025-€2,000-€1,500-€1,000-€500€0Operating result 2023: -€1,377-€1,380Net result 2023: -€1,543-€1,540Operating result 2024: -€412-€412Net result 2024: -€563-€563Net result 2025: -€179-€179202320242025
The operating result stays negative: a loss of €412 in 2024 against €1,377 in 2023; the loss shrinks.
Key figures and ratios
2025 value · change against 2024
Solvency
100.0%▲
2024 · 99.0%
ROE
-0.5%▲
2024 · -1.4%
ROA
-0.5%▲
2024 · -1.4%
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 6,915 companies that looked in July 2024 the way this one looks now, 1.1% went bankrupt within 24 months and 91% are still going.

  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a small loss
1.1% went bankrupt
7.8% stopped otherwise
91% still going

A further 0.4% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 1.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.7%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 6,915 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 26 lines
Balance sheet Code20242025
Assets
Total assets20/58€39,966€39,375▼
Current assets29/58€39,966€39,375▼
Amounts receivable within one year40/41€36,284€35,578▼
Trade receivables40€1,120€940▼
Other amounts receivable41€35,163€34,637▼
Cash at bank and in hand54/58€3,682€3,798▲
Equity and liabilities
Total equity and liabilities10/49€39,966€39,375▼
Equity10/15€39,554€39,375▼
Contributions10/11€6,200€6,200=
Reserves13€33,354€33,175▼
Non-distributable reserves130/1€1,860€1,860=
Reserves not available under the articles1311€1,860€1,860=
Distributable reserves133€31,494€31,315▼
Amounts payable17/49€412-
Amounts payable within one year42/48€412-
Trade debts44€412-
Suppliers440/4€412-
Income statement Code20242025
Gross operating margin9900-€412-
Operating profit (loss)9901-€412-
Financial charges65/66B€152€179▲
Recurring financial charges65€152€179▲
Profit (loss) for the period before taxes9903-€563-€179▲
Profit (loss) for the period9904-€563-€179▲
Profit (loss) for the period to be appropriated9905-€563-€179▲
Appropriation of the result
Profit (loss) to be appropriated9906-€563-€179▲
Transfer from equity791/2€563€179▼

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Remuneration, social security and pensions62€32,640-----
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€3,917€651----
Other operating charges640/8€1,671€6----
Gross operating margin9900-€1,586-€1,650-€1,377-€412--
Operating profit (loss)9901-€39,814-€2,307-€1,377-€412--
Financial income75/76B€6,123-----
Recurring financial income75€289-----
Non-recurring financial income76B€5,834-----
Financial charges65/66B€572€268€166€152€179▲ 17.8%
Recurring financial charges65€542€268€166€152€179▲ 17.8%
Non-recurring financial charges66B€29-----
Profit (loss) for the period before taxes9903-€34,263-€2,575-€1,543-€563-€179▲ 68.3%
Income taxes67/77€30-----
Profit (loss) for the period9904-€34,293-€2,575-€1,543-€563-€179▲ 68.3%
Profit (loss) for the period to be appropriated9905-€34,293-€2,575-€1,543-€563-€179▲ 68.3%
Line20212022202320242025Change
Assets
Total assets20/58€48,432€42,861€40,717€39,966€39,375▼ 1.5%
Fixed assets21/28€651-----
Intangible fixed assets21€0-----
Tangible fixed assets22/27€651-----
Furniture and vehicles24€651-----
Current assets29/58€47,780€42,861€40,717€39,966€39,375▼ 1.5%
Amounts receivable within one year40/41€38,426€36,558€36,714€36,284€35,578▼ 1.9%
Trade receivables40€37,209€1,495€1,315€1,120€940▼ 16.1%
Other amounts receivable41€1,217€35,063€35,399€35,163€34,637▼ 1.5%
Cash at bank and in hand54/58€8,855€6,302€4,003€3,682€3,798▲ 3.1%
Deferred charges and accrued income490/1€500-----
Equity and liabilities
Total equity and liabilities10/49€48,432€42,861€40,717€39,966€39,375▼ 1.5%
Equity10/15€44,236€41,661€40,117€39,554€39,375▼ 0.5%
Contributions10/11€6,200€6,200€6,200€6,200€6,200=
Reserves13€38,036€35,461€33,917€33,354€33,175▼ 0.5%
Non-distributable reserves130/1€1,860€1,860€1,860€1,860€1,860=
Reserves not available under the articles1311€1,860€1,860€1,860€1,860€1,860=
Distributable reserves133€36,176€33,601€32,057€31,494€31,315▼ 0.6%
Amounts payable17/49€4,196€1,200€600€412--
Amounts payable within one year42/48€4,196€1,200€600€412--
Trade debts44€3,453€1,200€600€412--
Suppliers440/4€656--€412--
Bills of exchange payable441€2,797€1,200€600---
Taxes, remuneration and social security45€55-----
Taxes450/3€55-----
Other amounts payable47/48€688-----
Line20212022202320242025Change
Profit (loss) for the period9904-€34,293-€2,575-€1,543-€563-€179▲ 68.3%
+ Depreciation and write-downs630€3,917€651----
Operating cash flow (approximation)-€30,376-€1,924-€1,543-€563-€179▲ 68.3%
Change in cash--€2,552-€2,299-€321€116▲ 136%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 30-04-2027
2026
22-09
State Gazette act Resignation: Xavier GLORIEUX (director)
3 facts ▸
  • General meeting, 02-12-2025
  • Director resignation, Xavier GLORIEUX (director)
  • General meeting, unanimité, prise acte de la démission de Xavier GLORIEUX et l'accepte
28-05
NBB filing Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
2025
19-05
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 19 days late
2024
29-05
NBB filing Annual accounts filed
fiscal year 2023 · micro schema · 29 days late
2023
03-05
NBB filing Annual accounts filed
fiscal year 2022 · micro schema · 3 days late
2022
30-09
Financial Liquidity triplescurrent ratio 35.72
Current ratio from 11.39 to 35.72; short-term debt falls from €4,196 to €1,200.
23-05
NBB filing Annual accounts filed
fiscal year 2021 · micro schema · 23 days late
2021
30-09
Financial Weakest financial yearnet -€34,293
Net result drops to -€34,293, the lowest in the series; recovery starts the following year.
30-09
Financial Liquidity times 7current ratio 11.39
Current ratio from 1.69 to 11.39; short-term debt falls from €97,667 to €4,196.
2020
11-12
NBB filing Annual accounts filed
fiscal year 2020 · micro schema
30-09
Financial Back to profitnet €666
Net result €666 after 2 loss-making years.
25-03
NBB filing Annual accounts filed
fiscal year 2019 · micro schema
Show earlier events
2019
27-03
NBB filing Annual accounts filed
fiscal year 2018 · micro schema
2018
28-03
NBB filing Annual accounts filed
fiscal year 2017 · full schema
2017
31-03
NBB filing Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 2 acts read
About the unread acts

Of the 2 Belgian State Gazette acts we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
no sitting director, last change in 2026
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
Not every act has been read: a resignation may be missing here
1 of this company's 2 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Farciennes · 1 establishment unit since 2007
seat establishment approximate The establishment unit on the map
Ground area
718 m²
Building footprint
320 m²
Volume, LiDAR
1,465 m³
2 parcels, Wallonia · tallest building 8.5 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
Bemipharma
Rue Albert 1er(FAR) 22, 6240 FarciennesNACE 5227204
since 20072.158.327.006
2 parcels
Wallonia 2 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
52018D0499/00W002 Wallonia 410 m² 1 · 89 m² 8.5 m · 1 fl.
52018B0717/00H000 Wallonia 307 m² 1 · 231 m² 6.5 m · 1 fl.
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

1 person since 2026, 0 in office
Show
  • Board
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Xavier GLORIEUX
  • Director, until 22-09-2026
See the board, name and seat on a given date →

Structure & network

Owners and holdings

2 owners

Chain of control

  1. PHARMACIE BARBARIN LAURENCE 60%
  2. BEMIPHARMA

Highest known parent: PHARMACIE BARBARIN LAURENCE. The sources do not say who stands above it.

Owners 2

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

No current directors or connected companies found in the register.

Recognitions · licences · registrations

Food safety, FASFC

1 site
Farciennes2.158.327.006
1 permission
Apotheek (LM>3 maand) · since 01-01-2008

Identification & contact

Identification
Legal formPrivate limited company (pre-2019)
Founded18-12-2006
Fiscal year end30-09
E-invoicing
Not found in the Peppol register

No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.

What can you do?

Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.

If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if electronically, with their agreement on a secure alternative. That invoice is valid; the customer risks a penalty. FPS Finance

Register as of 28 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.